Neuland Laboratories Limited
NSE: NEULANDLAB BSE: NEULANDLAB
Prev Close
13840
Open Price
13890
Volume
72,265
Today Low / High
13725 / 14315
52 WK Low / High
8651.05 / 18100
Range
13,215 - 14,606
Prev Close
13849.1
Open Price
13456.2
Volume
5,086
Today Low / High
13456.2 / 14300
52 WK Low / High
8669.4 / 18089.55
Range
13,209 - 14,600
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 13910 (target range: 13,215 - 14,606), reflecting a change of 70 (0.50578%). On the BSE, it is listed at 13904.45 (target range: 13,209 - 14,600), showing a change of 55.35 (0.39966%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Neuland Laboratories Limited Graph
Neuland Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Neuland Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 13,910.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 13,904.45 | 14,043.49 | 12,639.15 - 15,447.84 |
14,182.54 | 11,346.03 - 17,019.05 | ||
14,321.58 | 10,025.11 - 18,618.06 | ||
Bearish Scenario | 13,904.45 | 13,765.41 | 12,388.86 - 15,141.95 |
13,626.36 | 10,901.09 - 16,351.63 | ||
13,487.32 | 9,441.12 - 17,533.51 |
Overview of Neuland Laboratories Limited
ISIN
INE794A01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
92,837
Market Cap
178,463,909,000
Last Dividend
12
Official Website
IPO Date
2008-10-13
DCF Diff
-821.78
DCF
14,732
Financial Ratios Every Investor Needs
Stock Dividend of NEULANDLAB
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2025-07-18 | July 18, 25 | 12 | 12 | 2025-07-18 | 2025-08-08 | |
2024-07-12 | July 12, 24 | 14 | 14 | 2024-07-12 | 2024-08-30 | |
2023-07-11 | July 11, 23 | 10 | 10 | 2023-07-11 | 2023-08-26 | |
2022-07-14 | July 14, 22 | 5 | 5 | 2022-07-15 | 2022-09-01 | |
2021-06-29 | June 29, 21 | 3 | 3 | 2021-06-30 | 2021-08-03 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1,476.84 Cr | 750.51 Cr | 726.33 Cr | 0.4918 | 0.00 Cr | 0.00 Cr | 257.71 Cr | 260.11 Cr | 202.74 | 420.17 Cr | 0.1761 |
2024-03-31 | 1,558.58 Cr | 733.80 Cr | 824.78 Cr | 0.5292 | 43.50 Cr | 30.92 Cr | 531.81 Cr | 300.08 Cr | 233.89 | 474.82 Cr | 0.1925 |
2023-03-31 | 1,160.90 Cr | 613.79 Cr | 547.11 Cr | 0.4713 | 27.76 Cr | 29.89 Cr | 234.34 Cr | 163.52 Cr | 127.45 | 279.18 Cr | 0.1409 |
2022-03-31 | 923.33 Cr | 553.50 Cr | 369.83 Cr | 0.4005 | 0.36 Cr | 15.69 Cr | 96.09 Cr | 63.82 Cr | 49.74 | 140.40 Cr | 0.0691 |
2021-03-31 | 918.18 Cr | 554.72 Cr | 363.46 Cr | 0.3958 | 21.07 Cr | 13.49 Cr | 109.63 Cr | 80.63 Cr | 62.85 | 162.91 Cr | 0.0878 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 131.93 Cr | 2,179.88 Cr | 655.08 Cr | 1,524.8063 Cr | 157.14 Cr | 25.21 Cr | 385.76 Cr | 718.27 Cr | 0.00 Cr | 0.00 Cr | 1.53 Cr | 465.6859 Cr |
2024-03-31 | 87.58 Cr | 1,832.56 Cr | 549.86 Cr | 1,282.7048 Cr | 95.39 Cr | 7.81 Cr | 350.42 Cr | 568.61 Cr | 81.17 Cr | 0.00 Cr | 13.76 Cr | 427.6832 Cr |
2023-03-31 | 45.42 Cr | 1,579.76 Cr | 585.67 Cr | 994.0965 Cr | 128.45 Cr | 83.03 Cr | 279.23 Cr | 498.00 Cr | 136.56 Cr | 0.00 Cr | 0.00 Cr | 438.9570 Cr |
2022-03-31 | 5.09 Cr | 1,383.49 Cr | 542.99 Cr | 840.5008 Cr | 240.53 Cr | 235.44 Cr | 265.21 Cr | 486.58 Cr | 0.00 Cr | 0.00 Cr | 0.50 Cr | 363.1566 Cr |
2021-03-31 | 2.44 Cr | 1,324.79 Cr | 538.33 Cr | 786.4577 Cr | 182.29 Cr | 179.86 Cr | 247.61 Cr | 431.23 Cr | 63.61 Cr | 0.03 Cr | -7.68 Cr | 368.5109 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 317.3828 Cr | -298.1559 Cr | 24.9610 Cr | 110.9188 Cr | 44.3550 Cr | 131.9304 Cr | -206.4640 Cr | 346.3290 Cr | 55.3429 Cr | -17.9618 Cr | -35.3350 Cr |
2024-03-31 | 261.1767 Cr | -149.6868 Cr | -69.2818 Cr | 117.5069 Cr | 42.1595 Cr | 87.5754 Cr | -143.6698 Cr | 300.0789 Cr | -39.4402 Cr | -12.8299 Cr | -71.1885 Cr |
2023-03-31 | 237.2119 Cr | -61.4985 Cr | -135.7956 Cr | 171.0834 Cr | 40.3245 Cr | 45.4159 Cr | -66.1285 Cr | 215.2129 Cr | -113.5815 Cr | -6.4149 Cr | -14.0233 Cr |
2022-03-31 | 60.3888 Cr | -95.5163 Cr | 37.7215 Cr | -37.2972 Cr | 2.6558 Cr | 5.0914 Cr | -97.6860 Cr | 82.1625 Cr | 20.3341 Cr | -3.8490 Cr | -17.6024 Cr |
2021-03-31 | 189.3617 Cr | -84.4237 Cr | -113.6604 Cr | 83.9647 Cr | -8.7679 Cr | 2.4356 Cr | -105.3970 Cr | 105.3335 Cr | -89.6629 Cr | -2.5660 Cr | -28.0603 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 328.36 Cr | 171.99 Cr | 156.37 Cr | 0.4762 | 34.18 Cr | 27.81 Cr | 21.67 | 58.54 Cr | 0.0847 |
2024-12-31 | 398.03 Cr | 205.72 Cr | 192.31 Cr | 0.4831 | 70.30 Cr | 101.59 Cr | 79.18 | 146.28 Cr | 0.2552 |
2024-09-30 | 310.84 Cr | 159.76 Cr | 151.09 Cr | 0.4861 | 46.15 Cr | 32.84 Cr | 25.60 | 66.56 Cr | 0.1057 |
2024-06-30 | 439.60 Cr | 302.46 Cr | 137.15 Cr | 0.3120 | 107.08 Cr | 97.87 Cr | 76.28 | 148.79 Cr | 0.2226 |
2024-03-31 | 385.01 Cr | 180.02 Cr | 204.99 Cr | 0.5324 | 90.45 Cr | 67.56 Cr | 52.66 | 109.35 Cr | 0.1755 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 131.93 Cr | 107.68 Cr | 368.72 Cr | 315.72 Cr | 385.76 Cr | 1,139.50 Cr | 718.27 Cr | 2,179.88 Cr | 655.08 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 190.36 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,395.21 Cr |
2024-09-30 | 72.47 Cr | 125.03 Cr | 197.51 Cr | 305.93 Cr | 386.46 Cr | 966.48 Cr | 669.99 Cr | 1,943.80 Cr | 548.59 Cr |
2024-06-30 | -87.58 Cr | 175.15 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | 87.58 Cr | 0.00 Cr | 0.00 Cr | -1,282.70 Cr |
2024-03-31 | 87.58 Cr | 15.01 Cr | 102.59 Cr | 375.99 Cr | 350.42 Cr | 921.08 Cr | 568.61 Cr | 1,832.56 Cr | 549.86 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 27.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-12-31 | 101.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | 32.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | 97.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 67.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2014-08-13 | August 13, 14 | 523:500 |
2012-03-21 | March 21, 12 | 289:250 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,733.80 | ₹4,159,871,664,000.00 | ₹2,318,664.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,650.00 | ₹1,765,368,850,000.00 | ₹226,973.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,730.60 | ₹1,262,602,917,000.00 | ₹439,520.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,292.10 | ₹1,075,456,274,108.00 | ₹1,386,961.00 |
Mankind Pharma Limited | MANKIND | ₹2,575.50 | ₹1,062,982,921,380.00 | ₹763,328.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.15 | ₹1,001,349,784,500.00 | ₹775,382.00 |
Lupin Limited | LUPIN | ₹1,984.60 | ₹906,460,096,200.00 | ₹754,124.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.00 | ₹672,568,716,000.00 | ₹672,249.00 |
Alkem Laboratories Limited | ALKEM | ₹5,099.60 | ₹609,733,674,000.00 | ₹69,765.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,153.60 | ₹607,748,073,600.00 | ₹786,090.00 |
Laurus Labs Limited | LAURUSLABS | ₹881.45 | ₹475,603,095,050.00 | ₹5,551,173.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,529.50 | ₹388,040,268,000.00 | ₹501,348.00 |
Cohance Lifesciences Limited | COHANCE | ₹997.40 | ₹381,572,333,779.00 | ₹30,739.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,800.50 | ₹349,816,056,000.00 | ₹68,739.00 |
Piramal Enterprises Limited | PEL | ₹1,287.60 | ₹291,870,592,800.00 | ₹4,377,271.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,782.60 | ₹278,652,466,800.00 | ₹198,162.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,684.80 | ₹273,744,619,200.00 | ₹253,355.00 |
Eris Lifesciences Limited | ERIS | ₹1,816.60 | ₹247,415,470,200.00 | ₹258,998.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,340.00 | ₹233,500,000,000.00 | ₹39,783.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.60 | ₹198,056,878,800.00 | ₹43,245.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,236.30 | ₹196,919,100,300.00 | ₹1,978,762.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹13,910.00 | ₹178,463,909,000.00 | ₹72,265.00 |
NATCO Pharma Limited | NATCOPHARM | ₹973.15 | ₹174,300,896,500.00 | ₹709,365.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,145.80 | ₹163,105,905,860.00 | ₹121,630.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹492.15 | ₹119,417,244,600.00 | ₹954,418.00 |
Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,631,800.00 | ₹41,877.00 |
Shilpa Medicare Limited | SHILPAMED | ₹919.15 | ₹89,884,505,735.00 | ₹41,687.00 |
Strides Pharma Science Limited | STAR | ₹945.35 | ₹87,126,008,445.00 | ₹401,712.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹946.50 | ₹85,785,667,830.00 | ₹174,284.00 |
FDC Limited | FDC | ₹484.45 | ₹78,873,304,500.00 | ₹30,593.00 |
Suven Life Sciences Limited | SUVEN | ₹269.30 | ₹58,727,328,200.00 | ₹85,394.00 |
Innova Captab Limited | INNOVACAP | ₹917.50 | ₹52,503,873,275.00 | ₹36,415.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹151.93 | ₹49,304,627,460.00 | ₹195,988.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹522.25 | ₹47,665,757,500.00 | ₹446,949.00 |
Sequent Scientific Limited | SEQUENT | ₹175.86 | ₹44,023,913,100.00 | ₹235,318.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹619.85 | ₹43,641,035,130.00 | ₹39,695.00 |
Hikal Limited | HIKAL | ₹329.80 | ₹40,664,669,800.00 | ₹316,649.00 |
Gufic Biosciences Limited | GUFICBIO | ₹404.55 | ₹40,567,464,900.00 | ₹352,761.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,405.80 | ₹39,789,526,200.00 | ₹52,499.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹705.15 | ₹35,764,573,365.00 | ₹37,012.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹59.69 | ₹32,707,374,260.00 | ₹1,444,289.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹651.90 | ₹31,390,940,700.00 | ₹124,331.00 |
Indoco Remedies Limited | INDOCO | ₹324.50 | ₹29,934,443,550.00 | ₹64,322.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹100.29 | ₹29,437,822,830.00 | ₹15,953,556.00 |
Alembic Limited | ALEMBICLTD | ₹114.24 | ₹29,334,775,566.00 | ₹212,418.00 |
Key Executives
Gender: female
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1944
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1972
Gender: male
Year Born: 1975
Gender: male
Year Born:
Gender: male
Year Born: 1968
Gender: male
Year Born: 1979
Gender: male
Year Born:
FAQs about Neuland Laboratories Limited
The CEO is Davuluri Sucheth Rao.
The current price is ₹13,910.00.
The range is ₹8651.05-18100.
The market capitalization is ₹17,846.39 crores.
The dividend yield is 0.09%.
The P/E ratio is 68.61.
The company operates in the Healthcare sector.
Overview of Neuland Laboratories Limited (ISIN: INE794A01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹17,846.39 crores and an average daily volume of 92,837 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹12.